Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
FDA establishment 3017374013, Brooksville, Florida, United States. Part of PQ Pharmacy's FDA records. Every inspection FDA has posted for the site, with its outcome and cited regulations.
Inspections: 2
Official action indicated: 1
Form 483s posted: 5
Warning letters: 1
Inspections by fiscal year
FY2018 to FY2027 to date; 1 classified OAI
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
21 CFR 211.192. Written record of investigation incomplete Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
21 CFR 211.113(b). Procedures for sterile drug products Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
21 CFR 211.100(a). Absence of Written Procedures Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
21 CFR 211.42(c)(10)(iv). Environmental Monitoring System Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Official Action Indicated (OAI)
Oct 27, 2022
Drugs · Drug Quality Assurance
7 cited references
21 CFR 211.166(a)(3). Valid stability test methods The written stability program for drug products does not include reliable test methods.
FDCA 503B(b)(2)(A). Outsourcing facility, compounded drug report follow up Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.
21 CFR 211.42(c)(10)(v). Cleaning System Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
21 CFR 211.22(a). Authority lacking to review records, investigate errors The quality control unit lacks authority to review production records to assure that no errors have occurred and fully investigate errors that have occurred.
21 CFR 211.22(d). Procedures not in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not fully followed.
21 CFR 211.166(b). Adequate number of batches on stability An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
FDCA 503B(b)(2)(A). Outsourcing facility, compounded drug report during registration Your outsourcing facility did not submit a report to FDA upon initial registration as an outsourcing facility identifying the drugs compounded during the previous six month period.
Voluntary Action Indicated (VAI)
Form 483 observations
What FDA investigators wrote up at the end of 5 inspections, from the 483s FDA posted; newest first, the 4 newest
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Records of the inspections of automatic, mechanical or electronic equipment, including computers or related systems are not maintained.
The responsibilities and procedures applicable to the quality control unit are not in writing.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not written and followed.
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that drug product containers conform to appropriate standards of identity, strength…
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
The quality control unit lacks authority to review production records to assure that no errors have occurred and fully investigate errors that have occurred.
The responsibilities and procedures applicable to the quality control unit are not fully followed.
An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
The written stability program for drug products does not include reliable test methods.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Publishing draft principles 4) Holding EWG Meetings Ensuring Agency internal clearances Endorsement by ICH
Holding a global conference to provide updates 9 Development Strategy for E6(R3) Annex 1 Considerations for interventional clinical trials Annex 2 Additional considerations When complete, E6(R3) will be composed of an overarching…
CTs should be scientifically sound for their intended purpose and based on robust and current scientific knowledge and approaches.
CTs should be designed and conducted by qualified individuals.
Quality should be built into the scientific and operational design and conduct of CTs.
CT processes, measures and approaches should be implemented in a way that is proportionate to the risks to participants and to the importance of the data collected.
CTs should be described in a clear, concise and operationally feasible.
CTs should generate reliable results.
Roles and responsibilities in CTs should be clear and documented appropriately.
Investigational products used in a CT should be manufactured in accordance with applicable Good Manufacturing Practice .... and be stored, shipped, handled and disposed of in accordance with the product specifications .....
Warning letters
Letters naming this establishment; each opens the letter
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. Recalls come from FDA's enforcement reports (iRES), one row per recall even when it covers many lots. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm. Form 483 observations are read by Arca from the 483s FDA posts in its FOIA reading room, most of them scans: the first sentence of each observation, with redactions as FDA made them. FDA posts 483s for a minority of inspections.FDA Data Dashboard, warning letters and enforcement reports